United States

FDA approves BELVIQ XR weight loss tablets

Thursday, July 21, 2016

The FDA has approved Eisai and Arena Pharmaceuticals’ New Drug Application (NDA) for BELVIQ XR (lorcaserin HCl) CIV extended-release 20mg tablets. The new formulation of lorcaserin will offer patients a once-a-day dosing option that may help them achieve and maintain weight loss. BELVIQ XR is expected to be available in the fall of 2016. In connection with the approval, Arena will receive a $10 million milestone payment.

[Read More]

EMD Serono to open $115M life science campus in Massachusetts

Tuesday, July 19, 2016

EMD Serono, known as Merck outside of the U.S. and Canada, a science and technology company, has announced plans to build a new campus in Burlington, Massachusetts, that will serve as a major hub for the North American life science business of Merck. The 280,000-square-foot facility will include a customer collaboration laboratory and training center as well as office space.

[Read More]

Study: Mentorship programs build long-term research careers

Tuesday, July 19, 2016

A public-private mentored research program based at the NIH called the NIH Clinical Research Training Program (CRTP) has helped foster the careers of research-oriented medical and dental students, and similar programs may help bolster the dwindling pipeline of biomedical researchers and clinician-scientists, according to a study now available electronically in Academic Medicine.

[Read More]

NIH expands investment in HIV cure research

Tuesday, July 19, 2016

The NIH has awarded approximately $30 million in annual funding over the next five years to six research collaborations working to advance basic medical science toward an HIV cure. The awards comprise the second iteration of the Martin Delaney Collaboratory: Towards an HIV-1 Cure program and are a part of President Barack Obama’s pledge to invest in HIV cure research. The research program is supported by the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute on Drug Abuse, the National Institute of Mental Health and the National Institute of Neurological Disorders and Stroke, all part of the NIH.

[Read More]

Virginia Cancer Specialists receives Clinical Trials Research Award

Thursday, July 14, 2016

Virginia Cancer Specialists (VCS), Northern Virginia’s premier cancer care center with more than 40 years of service to patients battling cancer and blood diseases, has announced it is one of only three community oncology practices in the country recognized this year by the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) for its commitment to providing high-quality clinical trials to patients.

[Read More]

AbbVie receives Rare Pediatric Disease Designation for ABT-414

Tuesday, July 12, 2016

AbbVie, a global biopharmaceutical company, announced that the FDA granted Rare Pediatric Disease Designation for ABT-414, an investigational antibody drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR), for the treatment of pediatric patients with EGFR-amplified Diffuse Intrinsic Pontine Glioma (DIPG), known to be highly aggressive and difficult to treat brain tumors found at the base of the brain.

[Read More]